- About UsOpenClose
- LeadershipOpenClose
- BoardOpenClose
- TechnologyOpenClose
- PublicationsOpenClose
- PipelineOpenClose
- For PatientsOpenClose
- For InvestorsOpenClose
- NewsroomOpenClose
- Media CoverageOpenClose
- Press ReleasesOpenClose
Carisma is developing CT-0508 to target HER2-positive solid tumors. While its expression in normal tissues is low, HER2 is highly expressed in a wide range of solid tumors and plays an active role in both malignant transformation and tumor aggressiveness by promoting cancer cell proliferation, invasion and metastasis.
CT-0508 is a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-Macrophage). In pre-clinical studies Carisma’s CAR-Macrophage cell therapies have demonstrated the ability to traffic into the tumor, phagocytose and kill cancer cells, warm-up the tumor microenvironment, and attract and activate cells of the adaptive immune system, delivering a lasting attack against the cancer.
Carisma scientific leaders discuss the findings from the CT-0508 clinical trial; immunotherapy leveraging CAR-macrophages in patients with HER2 overexpressing solid tumors. The landmark study of CT-0508 is the first of the engineered myeloid cell platform, which has applicability across hard-to-treat cancers and other serious illnesses.
CT-0508 is the first CAR-Macrophage cell therapy to enter clinical trials. Preclinical trials showed that the treatment has the potential to overcome the key challenges faced by other cell therapies in treating solid tumors.
In March 2024, Carisma made the decision to cease development of CT-0508, a HER2-targeting CAR-Macrophage, given its prioritization of CT-0525 as its lead HER2 product candidate. Although Carisma plans to continue ongoing activities under its open label Phase 1 clinical trial of CT-0508, enrollment of new patients will be suspended in line with the clinical judgment of the clinical site principal investigator. All patients currently enrolled or in screening will continue participation per protocol through the end of study milestone and will complete all required activities.
For more on CT-0508 and our clinical trials, visit our patient clinical trial website.
Clinical Trials